Skip to main content
NVDA+0.10%AAPL+0.03%MSFT+0.29%GOOGL+1.19%AMZN+0.25%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA+0.22%META-0.07%LLY+0.22%BRK-B-1.02%MU+1.33%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK-0.10%CVX-1.59%0700.HK+0.85%COST-1.30%CSCO+1.03%ORCL+3.55%KO-1.64%PG-0.45%UNH-0.08%BAC+0.32%1816.HK-29.06%3988.HK-0.62%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%AMAT+2.15%AP2d+2.18%0857.HK-2.09%GE+3.20%0939.HK-0.43%1288.HK-0.11%0005.HK+2.43%LRCX+1.41%NVS+1.98%MS+1.91%NZDUSD-1.65%AUDNZD+1.63%NZDSGD-1.27%NZDMXN-1.26%NZDCAD-1.23%GBPNZD+1.08%NZDCHF-1.05%NZDJPY-0.98%EURNZD+0.92%EURUSD-0.72%EURAUD-0.69%USDJPY+0.68%AUDJPY+0.65%USDCHF+0.60%GBPUSD-0.60%AUDCHF+0.58%GBPAUD-0.56%USDCAD+0.43%GBPTRY+0.41%AUDCAD+0.39%GBPHKD+0.32%GBPMXN-0.28%EURCAD-0.28%USDTRY+0.28%CADJPY+0.26%GBPCAD-0.19%CADCHF+0.17%USDZAR+0.17%USDILS+0.16%AUDSGD+0.15%EURZAR+0.15%EURCHF-0.14%CHFNOK-0.14%AUDDKK+0.13%USDTHB+0.12%EURGBP-0.12%PLNJPY-0.11%CHFSEK-0.11%CHFJPY+0.09%USDPLN+0.09%GBPZAR+0.08%EURNOK-0.08%GBPJPY+0.07%SGDJPY-0.07%USDNOK-0.06%EURPLN+0.06%USDMXN+0.06%AUDNOK+0.05%EURSEK-0.04%USDSGD+0.04%USDHKD+0.04%GBPSGD-0.04%USDCOP-0.04%EURJPY-0.04%CHFSGD-0.03%NOKJPY+0.03%AUDUSD-0.03%USDSEK-0.03%EURSGD+0.03%USDDKK+0.02%EURHKD-0.02%USDCNH-0.01%GBPCHF-0.01%EURDKK0.00%EURCNH0.00%EURCZK0.00%USOIL+1.20%GAGUSD-0.97%XAGUSD-0.97%UKOIL+0.95%XPTUSD-0.70%GAUUSD-0.56%XAUUSD-0.56%XNGUSD+0.49%HG1-0.27%COTTON-0.26%S1+0.16%W1+0.09%BTCUSD+1.18%ETHUSD+23.96%USDTUSD0.00%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.76%ZECUSDT+7.24%DOGEUSD+20.65%XMRUSDT+0.96%LINKUSD+25.58%BCHUSDT+6.57%XLMUSD+1.72%UNIUSD+0.88%LTCUSD+17.89%SUIUSD+2.48%HBARUSDT-0.68%TONUSD+41.71%TAOUSDT+2.94%AAVEUSD-0.45%DOTUSDT-0.40%ICPUSDT-0.88%ONDOUSDT+0.89%WLDUSDT+0.37%ARBUSDT+0.92%JUPUSDT+1.56%ATOMUSDT+0.40%INJUSDT-0.27%STXUSDT-1.08%TIAUSDT-1.79%FETUSDT+4.21%PYTHUSDT-2.43%SEIUSDT+2.45%IMXUSDT+0.79%GRTUSDT+1.98%OPUSDT+1.59%WIFUSDT+0.50%IOTAUSDT+1.26%POLUSDT+1.26%AXSUSDT+1.46%EOSUSDT+1.53%FARTCOINUSDT+4.55%DYDXUSDT+3.16%GALAUSDT+2.72%ORDIUSDT+4.01%RONINUSDT+1.89%NOTUSDT+4.64%NVDA+0.10%AAPL+0.03%MSFT+0.29%GOOGL+1.19%AMZN+0.25%TSM+2.95%SPCX+1.14%AVGO+4.00%TSLA+0.22%META-0.07%LLY+0.22%BRK-B-1.02%MU+1.33%SKHY+1.92%WMT-0.81%AMD+5.45%JPM+0.52%V-0.57%XOM-2.53%JNJ+0.91%ASMLa+2.80%MA-0.59%ABBV-0.10%INTC+3.61%1398.HK-0.10%CVX-1.59%0700.HK+0.85%COST-1.30%CSCO+1.03%ORCL+3.55%KO-1.64%PG-0.45%UNH-0.08%BAC+0.32%1816.HK-29.06%3988.HK-0.62%CAT+3.06%DELL+7.38%HD-0.28%PM+0.37%AMAT+2.15%AP2d+2.18%0857.HK-2.09%GE+3.20%0939.HK-0.43%1288.HK-0.11%0005.HK+2.43%LRCX+1.41%NVS+1.98%MS+1.91%NZDUSD-1.65%AUDNZD+1.63%NZDSGD-1.27%NZDMXN-1.26%NZDCAD-1.23%GBPNZD+1.08%NZDCHF-1.05%NZDJPY-0.98%EURNZD+0.92%EURUSD-0.72%EURAUD-0.69%USDJPY+0.68%AUDJPY+0.65%USDCHF+0.60%GBPUSD-0.60%AUDCHF+0.58%GBPAUD-0.56%USDCAD+0.43%GBPTRY+0.41%AUDCAD+0.39%GBPHKD+0.32%GBPMXN-0.28%EURCAD-0.28%USDTRY+0.28%CADJPY+0.26%GBPCAD-0.19%CADCHF+0.17%USDZAR+0.17%USDILS+0.16%AUDSGD+0.15%EURZAR+0.15%EURCHF-0.14%CHFNOK-0.14%AUDDKK+0.13%USDTHB+0.12%EURGBP-0.12%PLNJPY-0.11%CHFSEK-0.11%CHFJPY+0.09%USDPLN+0.09%GBPZAR+0.08%EURNOK-0.08%GBPJPY+0.07%SGDJPY-0.07%USDNOK-0.06%EURPLN+0.06%USDMXN+0.06%AUDNOK+0.05%EURSEK-0.04%USDSGD+0.04%USDHKD+0.04%GBPSGD-0.04%USDCOP-0.04%EURJPY-0.04%CHFSGD-0.03%NOKJPY+0.03%AUDUSD-0.03%USDSEK-0.03%EURSGD+0.03%USDDKK+0.02%EURHKD-0.02%USDCNH-0.01%GBPCHF-0.01%EURDKK0.00%EURCNH0.00%EURCZK0.00%USOIL+1.20%GAGUSD-0.97%XAGUSD-0.97%UKOIL+0.95%XPTUSD-0.70%GAUUSD-0.56%XAUUSD-0.56%XNGUSD+0.49%HG1-0.27%COTTON-0.26%S1+0.16%W1+0.09%BTCUSD+1.18%ETHUSD+23.96%USDTUSD0.00%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.76%ZECUSDT+7.24%DOGEUSD+20.65%XMRUSDT+0.96%LINKUSD+25.58%BCHUSDT+6.57%XLMUSD+1.72%UNIUSD+0.88%LTCUSD+17.89%SUIUSD+2.48%HBARUSDT-0.68%TONUSD+41.71%TAOUSDT+2.94%AAVEUSD-0.45%DOTUSDT-0.40%ICPUSDT-0.88%ONDOUSDT+0.89%WLDUSDT+0.37%ARBUSDT+0.92%JUPUSDT+1.56%ATOMUSDT+0.40%INJUSDT-0.27%STXUSDT-1.08%TIAUSDT-1.79%FETUSDT+4.21%PYTHUSDT-2.43%SEIUSDT+2.45%IMXUSDT+0.79%GRTUSDT+1.98%OPUSDT+1.59%WIFUSDT+0.50%IOTAUSDT+1.26%POLUSDT+1.26%AXSUSDT+1.46%EOSUSDT+1.53%FARTCOINUSDT+4.55%DYDXUSDT+3.16%GALAUSDT+2.72%ORDIUSDT+4.01%RONINUSDT+1.89%NOTUSDT+4.64%
CL

Caris Life Sciences, Inc. (CAI)

NASDAQ • Healthcare

$33.67
+$1.21 (+3.7%)
Market closed

Last close at October 27, 2026 at 20:00 UTC

Open$32.4
Day Range$32.07 - $34.06
Avg. Volume (3M)3.5M
Market Cap$9.5B
P/E Ratio91.0
52 Week Range
$14.19$34.06
Next EarningsIn 7 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$263.7M100%
Gross Profitminus cost of goods$179.5M68%
Operating Incomeminus R&D and overhead$26.9M10%

Fundamentals & Financials

Revenue (TTM)
$989.6M
Net Income (TTM)
$105.1M
EPS (TTM)
$0.37
ROA (TTM)
8.55%
Current Ratio
5.53
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+2700.0%Q1 2026$0.28
+91.0%Q2 2026$0
-139.2%Q3 2026$0
Next

Nov 4

in 7 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -139.2%

Caris Life Sciences’ revenue topped consensus as sales rose 45.4% to about $263.7 million in the second fiscal quarter of 2026 (period ended June 30, 2026), based on preliminary results reported August 5, 2026. Revenue of $263.7 million topped the $238.1 million estimate, +10.8%, and was up from about $181.4 million a year ago, with the company’s molecular profiling and oncology-focused diagnostics platform (including MI Profile and Caris Assure) underpinning the quarter’s scale. Profitability tracked higher volume, with gross profit of roughly $179.6 million translating to a gross margin of about 68%, while operating income came in near $26.9 million and operating margin stood around 10%. Cash generation was also positive, as Caris produced operating cash flow of about $61.4 million, and it repurchased roughly $21.4 million of stock during the period. Consensus for the next period calls for EPS of $0.02 on revenue of $255.5 million.

Next report — what to expect

Caris Life Sciences, Inc. (CAI) reports on November 4, 2026. Wall Street is looking for EPS of $0.03 on revenue of $256.3 million. For trailing context, revenue grew +45.4% year over year last quarter. The company has beaten EPS in 5 of its 8 most recent quarters.

View full earnings history

About Caris Life Sciences, Inc.

Caris Life Sciences, Inc. develops molecular diagnostics and research tools for oncology, operating in healthcare and biotechnology and trading on the NASDAQ as CAI. Its platform analyzes tumor and blood samples to guide cancer treatment and support drug development, and it generated $812.0 million in revenue in FY2025.

Name
Caris Life Sciences, Inc.
CEO
David Dean Halbert
Website
www.carislifesciences.com
Industry
Healthcare
Year Founded
2008
Employees
1,846

Today's Snapshot

AI-generated

CAI closed 3.7% higher, within reach of the top of its 52-week range. BTIG, a brokerage, raised Caris Life Sciences’ price target to $38 from $33. CAI reports earnings on 4 November.

Trading Volume

Above 10d avg 2.9M

3.3M

vs S&P 500 Today

Strong Outperformance

+3.05%

Updated: October 27, 2026 at 20:18 UTC

Technical Indicators

6 Buy1 Neutral1 Sell
CAI is trading at 33.67 and exhibits a strong technical bias driven by a robust trend and constructive momentum. ADX at 40.61 confirms a powerful uptrend while MACD and CCI readings are positive, and the price sits well above its short-, medium- and 200-day averages, indicating broad moving-average support. On-balance volume is supportive, although short-term oscillators show overbought readings and ATR implies elevated intraday volatility of roughly 5.3%. Technical takeaway: Strong Buy — trend and breadth are confirming the advance, but short-term overbought readings and higher volatility warrant attention.
All signals
  • EMA (5 indicators)$24.15 - $31.74
    Buy
  • RSI (14)66.31
    Neutral
  • Stochastic %K (14, 3, 3)93.37
    Sell
  • MACD Level (12, 26)1.26
    Buy

Peers & Related Assets

ADPTAdaptive Biotechnologies Corporation
$27.66+5.3%
NEONeoGenomics, Inc.
$17.27+3.5%
WGSGeneDx Holdings Corp.
$62.74+2.4%
CSTLCastle Biosciences, Inc.
$34.51+3.6%
PSNLPersonalis, Inc.
IMDXInsight Molecular Diagnostics Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.